expression of 5-hydroxytryptamine (5-HT)1A, 5-HT2A, and 5-HT7 receptors. J Neurosci
24:4807– 4817
Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of
cannabidiol, aCannabis sativaconstituent. Current Drug Safe 6:237– 249
Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB,
Mechoulam R, Di Marzo V (2001a) Molecular targets for cannabidiol and its synthetic
analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic
hydrolysis of anandamide. Br J Pharmacol 134:845– 852
Bisogno T, HanušL, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB,
Mechoulam R, Di Marzo V (2001b) Molecular targets for cannabidiol and its synthetic
analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic
hydrolysis of anandamide. Br J Pharmacol 134:845– 852
Carlini EA, Leite JR, Tannhauser M, Berardi AC (1973) Letter: Cannabidiol andCannabis sativa
extract protect mice and rats against convulsive agents. J Pharm Pharmacol 25:664– 665
Carrier EJ, Auchampach JA, Hillard CJ (2006) Inhibition of an equilibrative nucleoside transporter
by cannabidiol: A mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA
103:7895– 7900
Consroe P, Wolkin A (1977) Cannabidiol–antiepileptic drug comparisons and interactions in
experimentally induced seizures in rats. J Pharmacol Exp Ther 201:26– 32
Consroe P, Benedito MA, Leite JR, Carlini EA, Mechoulam R (1982) Effects of cannabidiol
on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol
83:293– 298
Consroe P, Kennedy K, Schram K (1991) Assay of plasma cannabidiol by capillary gas
chromatography/ion trap mass spectroscopy following high-dose repeated daily oral admin-
istration in humans. Pharmacol Biochem Behav 40:517– 522
Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N,
Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic
patients. Pharmacology 21:175– 185
De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, Stott CG, Di
Marzo V (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP
channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163:1479– 1494
Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V,
Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E,
Whalley B, Friedman D (2014) Cannabidiol: pharmacology and potential therapeutic role in
epilepsy and other neuropsychiatric disorders. Epilepsia 55:791– 802
Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A,
Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J,
Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR (2016) Cannabidiol in patients with
treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 15:270– 278
During MJ, Spencer DD (1992) Adenosine: a potential mediator of seizure arrest and postictal
refractoriness. Ann Neurol 32:618– 624
Fasinu PS, Phillips S, ElSohly MA, Walker LA (2016) Current status and prospects for
cannabidiol preparations as new therapeutic agents. Pharmacotherapy 36:781– 796
Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J
(2013) Cannabidiol for neurodegenerative disorders: important new clinical applications for
this phytocannabinoid? Br J Clin Pharmacol 75:323– 333
Gallily R, Yekhtin Z, HanušL (2015) Overcoming the bell-shaped dose-response of cannabidiol
by using cannabis extract enriched in cannabidiol. Pharmacol Pharm 6:75– 85
Gaoni Y, Mechoulam R (1968) The ISO-tetrahydrocannabinols. Isr J Chem 6:679– 690
Gofshteyn JS, Wilfong A, Devinsky O, Bluvstein J, Charuta J, Ciliberto MA, Laux L, Marsh ED
(2016) Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome
(FIRES) in the acute and chronic phases. J child Neurol [Epub ahead of print]
Guy GW, Robson PJ (2003) A phase I, double blind, three-way crossover study to assess the
pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually
258 B.F. Thomas